A phase I trial of intravenous interleukin-6 in patients with advanced cancer.
Eighteen patients were treated with escalating doses of recombinant, Escherichia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 micrograms/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 micrograms/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.
Weber
J
J
Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892.
Gunn
H
H
Yang
J
J
Parkinson
D
D
Topalian
S
S
Schwartzentruber
D
D
Ettinghausen
S
S
Levitt
D
D
Rosenberg
S A
SA
D000209:Acute-Phase Proteins / Q000187:drug effects; D000328:Adult; D001772:Blood Cell Count / Q000187:drug effects; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000628:therapy*
D000209:Acute-Phase Proteins; D015850:Interleukin-6